Candidate Compounds Covid19

Version vom 6. Juni 2020, 20:18 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

current items will be put into the subsections. subsections with contents are marked with content. the others are pending data.

• reviews on covid drug development with content

• Patients on biologicals
• HMGB1, RAGE
• pre-Interleukin 6 with content
• post-Interleukin 6
• pre-TNFalpha
• post-TNFalpha
• pre-Interleukin 17
• post-Interleukin 17
• pre-Interleukin 1
• post-Interleukin 1
• Inflammasome

• NK-kappaB
• STAT 3
• JAK Janus Kinase
• Corticosteroids
• Cytokine absorbers
• Target Complement system
• Target Extracellular traps
• Anticoagulant in covid19
• Antioxidants
• Stem cells
• MDSC cells

• Hydroxychloroquine with content

• AV Remdesivir
• AV Lopinavir
• AV Ivermectin
• Interferons
• Vitamin D

• Statins
• Anorganic nutrients Magnesium
• Anorganic nutrients Selenium
• Anorganic nutrients Zinc

• Traditional Chinese Medicine
• Natural compounds
• Retargeted single compounds

• Target ACE2, Spike protein
• Target TMPRSS2, Spike protein
• Reconvalescent blood products, Passive vaccine with content
• Plasmapheresis

• Immunodeviation e.g. by adjuvants or other vaccinations
• Active vaccine with cotent

32162456 2020. Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1 3 Billion Compounds

Icatibant bradykinin antagonist
32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications

Arbidol retarget influenza
32373347 2020. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro

Macrolide antibiotics
32249257 2020. Macrolide treatment for COVID-19: Will this be the way forward?

Oleoylethanolamide
32327293 ä. Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19

Metronidazole retarget
32259129 2020. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen

Glutathione GSH antioxidant

• found in a forrest gump mode
• Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases

Chlorpromazine retarget

• paper

Zinc add-on

• call for trial

Selenium
32342979 ä. Association between regional selenium status and reported outcome of COVID-19 cases in China

Remdesivir retarget

• one hospital on...

32283108 ä. Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites
32020029 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Lauric acid nat. compd.

• call for trial

Nicotine nat. toxin

• france

Niclosamide
32125140 ä. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential

Microbiome as target
32356654 ä. Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection: Nanotechnology Roles

ACE2 as target
32286790 ä. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2
32333836 ä. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Garlic extracts
32363255 ä. Investigation into SARS-CoV-2 Resistance of Compounds in Garlic Essential Oil

Dipyridamole retarget
32318327 ä. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

stem cells
32257554 2020. Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia
32257537 2020. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
32283815 2020. Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use

Ivermectin
32330482 ä. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors responses

Various Leads

• 9 retargeted: ternatin4, zotatifin, plitidepsin; haloperidol, melperone, clemastine, cloperastine, pb28, progesterone
• paper in nature

32251767 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

Interferons
32275914 2020. Type 1 interferons as a potential treatment against COVID-19
32360182 2020. Antiviral activities of type I interferons to SARS-CoV-2 infection

32241793 2020. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies

Glucocorticoids

32149773 ä. Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial

CRISPR genome editing technology
32353252 ä. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza

Virus interference
32071427 2020. Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses

Antiviral agents Covid19
32231345 2020. Inhibition of SARS-CoV-2 (previously 2019-nCoV)infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

resilience enhancement
32229705 2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections
32311498 ä. The impact of nutrition on COVID-19 susceptibility and long-term consequences
32276453 2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats

psychoneuroimmunology
32234338 ä. Using psychoneuroimmunity against COVID-19

cannabinoids
32360437 ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?

Complementary & Traditional chinese medicine & Ethnopharm
32245701 ä. Is traditional Chinese medicine useful in the treatment of COVID-19?
32233641 2020. Network pharmacology-based analysis of the role of traditional Chinese herbal medicines in the treatment of COVID-19

• madagascar herbs

32229706 2020. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?
32037389 2020. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment
32334064 ä. Ayurveda and COVID-19: where psychoneuroimmunology and the meaning response meet
32361935 ä. Traditional Chinese and Western Medicines Jointly Beat COVID-19 Pandemic
32065348 ä. Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs
32308732 2020. Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China

Exercise
32311497 ä. The immunological case for staying active during the COVID-19 pandemic

Topical agents opening up the world of nano...

• on mouth rinses

32272008 2020. Early preemptive immunomodulators (corticosteroids) for severe pneumonia patients infected with SARS-CoV-2

32272196 2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology
32247038 2020. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19
32222466 2020. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China
32360516 ä. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

32335290 2020. A strategy targeting monocyte-macrophage differentiation to avoid pulmonary complications in SARS-Cov2 infection

32266375 ä. Inquiring into Benefits of Independent Activation of Non-Classical Renin-Angiotensin System in the Clinical Prognosis and Reduction of COVID-19 mortality

32301957 ä. Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19

32344167 ä. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study
32305181 ä. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection
32360083 ä. Modulation of Hb-O2 affinity to improve hypoxemia in COVID-19 patients

32277367 ä. Rheumatologists? perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets
32373721 2020. Low dose lung radiotherapy for COVID-19 pneumonia The rationale for a cost-effective anti-inflammatory treatment

32264963 2020. A new clinical trial to test high-dose vitamin C in patients with COVID-19

32241301 2020. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)
32318324 ä. Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival

32360420 ä. Cytokine storm intervention in the early stages of COVID-19 pneumonia

32335366 2020. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis
32333972 ä. Letter to the Editor in response to the article ?COVID-19 and diabetes: Can DPP4 inhibition play a role??
32333966 2020. COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications
32333969 ä. Response to COVID -19 and Diabetes: Can DPP4 Inhibition Play a Role? ? GLP-1 Might Play One Too
32283128 ä. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? on ace2 via adam17, nfkb via dpp4

32378648 2020. Rapid review for the anti-coronavirus effect of remdesivir

32325124 ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals

32249203 ä. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development

32379923 2020. Is BCG vaccination causally related to reduced COVID-19 mortality?
32333818 2020. COVID-19: lambda interferon against viral load and hyperinflammation

32228222 2020. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

C7118608 ä. A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System
32065055 2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
32346491 ä. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
32292627 ä. Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment

32347925 ä. Statin therapy in COVID-19 infection

32337546 ä. Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?
32282032 ä. Neprilysin inhibitor?angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients
32285293 ä. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV
C7129866 ä. Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19
32341100 2020. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective
32265310 ä. Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19
32271462 2020. Inositol and pulmonary function Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?
32271456 2020. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019
32271454 2020. Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19
32329881 2020. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience
32329879 2020. (Naturlal products: )An alternative approach to minimize the risk of coronavirus (Covid-19) and similar infections
32327396 ä. COVID-19 and Bacillus Calmette-Guerin: What is the Link?
32279655 2020. Can Hepatitis A Vaccine Provide Protection Against COVID-19?

32329380 2020. Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia
32312129 2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic
32117569 2020. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China

32374074 2020. Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease

32251729 ä. The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design
32363144 ä. Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin

32247692 ä. Faecal-oral transmission of SARS-COV-2: practical implications
32367287 ä. New evidence of SARS-CoV-2 transmission through the ocular surface

32251365 ä. Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy
32375153 2020. HMGB1: A Possible Crucial Therapeutic Target for COVID-19?
32186952 2020. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics

32362644 2020. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use

32366728 2020. Medical Education During the COVID-19 Pandemic: A Single Institution Experience
32366726 2020. Management of Asthma in Children during COVID-19 Pandemic
32366725 2020. COVID -19 Pandemic: The Challenges for Pediatric Oncology

32358227 2020. Demystifying BCG Vaccine and COVID-19 Relationship

32238614 2020. Measles Immunization: Worth Considering Containment Strategy for SARS-CoV-2 Global Outbreak
32321620 ä. Corticosteroid use for 2019-nCoV infection: A double-edged sword
32341599 2020. Is Immuno-modulation the Key to COVID-19 Pandemic?

32328406 ä. Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains

32342098 ä. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib
32372149 ä. SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?

32272396 ä. The Possible of Immunotherapy for COVID-19: a Systematic Review

32234466 ä. Coronavirus disease 2019 (COVID-19): current status and future perspectives

32259575 ä. BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19
32361028 ä. ?Amantadine disrupts lysosomal gene expression; a hypothesis for COVID19 treatment ?

32251731 ä. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection
32360231 ä. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ?
32335281 ä. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19

32283177 ä. Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 Infections

32179150 ä. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?
32147516 ä. Arguments in favour of remdesivir for treating SARS-CoV-2 infections

32226290 2020. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19
32226288 2020. Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective

32300868 ä. Balneotherapy and human immune function in the era of COVID-19
32321655 ä. An anti-oxidative therapy for ameliorating cardiac injuries of critically ill COVID-19-infected patients
32251768 2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

• Oxford vaccine failed in monkeys

32305009 ä. Investigating hypothiocyanite against SARS-CoV-2
32173576 2020. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression

32354030 2020. Functional Role of Dietary Intervention to Improve the Outcome of COVID-19: A Hypothesis of Work

32353978 2020. Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design

32368489 2020. The pathogenesis and alternative treatment of SARS-CoV2
32289016 2020. Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines
32125455 ä. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target
32347443 ä. Camostat mesilate therapy for COVID-19
32333086 ä. Remdesivir bei Patienten mit schwerer COVID-19
32378817 2020. Inhaled Nebulized Sodium Pyruvate Use in COVID-19 Patients

• Nature: The COVID-19 vaccine development landscape

32283237 ä. Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?
32278797 ä. The use of Janus kinase inhibitors in the time of SARS-CoV-2
32339701 ä. Potential role of Janus kinase inhibitors in COVID-19
32344070 ä. Calm before the storm: understanding the role of JAK inhibitors in COVID-19

32283123 ä. Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment
32336674 ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research
32361744 ä. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease
32196083 ä. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression
32317220 ä. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19

32284326 2020. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
32094225 2020. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

32306862 2020. Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes
32266873 2020. Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2?-O-ribose methyltransferase
32238078 2020. In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel

32374474 2020. Natural antiviral compound silvestrol modulates human monocyte-derived macrophages and dendritic cells

32352407 2020. Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists

32326602 2020. Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19
32326426 2020. COVID-19: A Recommendation to Examine the Effect of Mouthrinses with beta-Cyclodextrin Combined with Citrox in Preventing Infection and Progression

32289152 2020. COVID-19 and emerging viral infections: The case for interferon lambda
32302401 2020. Targeting potential drivers of COVID-19: Neutrophil extracellular traps
32359878 2020. Application of plasma exchange in association with higher dose CVVH in Cytokine Storm Complicating COVID-19

32171450 2020. Identification of potential cross-protective epitope between a new type of coronavirus (2019-nCoV) and severe acute respiratory syndrome virus
32173287 ä. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines
32373322 ä. Fighting COVID-19 with water dehydration of mucous glycans

32171872 ä. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
32333918 ä. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
32283153 ä. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-1
32362440 ä. Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases

32293807 2020. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID?19: initial assessment
32307268 2020. Active constituents and mechanisms of Respiratory Detox Shot, a traditional Chinese medicine prescription, for COVID-19 control and prevention: Network-molecular docking-LC?MSE analysis
32122812 2020. Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2)
32113846 ä. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus
32080993 2020. The Author s Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR
32080992 2020. Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR
32056407 2020. Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR

32356252 ä. COVID-19: Therapeutics and Their Toxicities
32356251 ä. Medical Toxicology and COVID-19: Our Role in a Pandemic
32052466 2020. Potential interventions for novel coronavirus in China: A systematic review

• on ivermectin

32331982 ä. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan
32236561 ä. Combating COVID-19 with Chloroquine

32296570 ä. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants?
32346490 ä. Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase
32324533 2020. Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients

32291198 2020. Impact of Nutrition and Diet on COVID-19 Infection and Implications for Kidney Health and Kidney Disease Management

32353597 ä. SARS-COV2 INFECTION AND LUNG CANCER PATIENTS: the potential role of IL17 target therapy
32281481 2020. Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review
32370758 2020. SARS-CoV-2 RNA polymerase as target for antiviral therapy

32313848 ä. Precision medicine in COVID-19: IL-1 beta a potential target

32321635 2020. Old and new antirheumatic drugs for the treatment of COVID-19

32317113 2020. COVID-19 therapeutic options for patients with kidney disease
32354636 ä. Blockade of SARS-CoV-2 infection by recombinant soluble ACE2
32367812 2020. Fyrsta meethfereth meeth tocilizumab vieth COVID-19 herlendis - sjukratilfelli
32365215 2020. Behandling med 4-aminokinoliner vid covid-19 kan ge allvarliga biverkningar
32278362 2020. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
32122468 2020. On the use of corticosteroids for 2019-nCoV pneumonia
32035018 2020. Reducing mortality from 2019-nCoV: host-directed therapies should be an option
32043983 2020. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
32032529 2020. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
32220278 2020. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?
32353328 2020. What policy makers need to know about COVID-19 protective immunity
32305088 2020. Flooded by the torrent: the COVID-19 drug pipeline
32278373 2020. Regulators split on antimalarials for COVID-19
32339473 ä. Probiotics and COVID-19: one size does not fit all
32199468 ä. Use of antiviral drugs to reduce COVID-19 transmission
32278361 ä. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19

32325035 ä. Plea for multitargeted interventions for severe COVID-19
32311322 ä. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19
32311324 ä. Hydroxychloroquine prophylaxis for COVID-19 contacts in India
32113510 2020. Convalescent plasma as a potential therapy for COVID-19
32113509 2020. COVID-19: combining antiviral and anti-inflammatory treatments
32304640 ä. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base
32368738 2020. Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology
32368737 2020. Preventing COVID-19-induced pneumonia with anticytokine therapy
32372026 ä. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis
32119961 2020. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
32222463 ä. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study
32251634 2020. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
32217117 2020. COVID-19: Melatonin as a potential adjuvant treatment
32360622 2020. Comment on Melatonin as a potential adjuvant treatment for COVID-19

32334009 2020. Correspondence COVID-19: Melatonin as a potential adjuvant treatment
32278693 2020. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach
32340389 2020. Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study
32359771 ä. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)
32198163 2020. Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection
32265331 2020. Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection
32328576 2020. Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)?
32296777 2020. Mesenchymal stem cells and management of COVID-19 pneumonia
32289117 2020. Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus
32292906 2020. The role of afferent pulmonary innervation in ARDS associated with COVID-19 and potential use of resiniferatoxin to improve prognosis: A review
C7147214 ä. Potential TRPV1 blockade to treat severe lung dysfunction in COVID-19 infection
32352081 ä. Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19
32352080 ä. Does vitamin D status impact mortality from SARS-CoV-2 infection?
32313880 ä. PAK1-blockers: Potential Therapeutics against COVID-19?
32292909 2020. Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies
32220710 2020. Renin-angiotensin system: The unexpected flaw inside the human immune system revealed by SARS-CoV-2
32361169 2020. Why not consider an endothelin receptor antagonist against SARS?CoV?2?

• riociguat?

32361100 2020. Amantadine as a drug to mitigate the effects of COVID-19
32353740 2020. Serum albumin-mediated strategy for the effective targeting of SARS-CoV-2
32353742 ä. Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19?
32353743 2020. Purposing Saikosaponins for the treatment of COVID-19
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)
32344303 ä. Oxytocin as a potential defence against Covid-19?
32361588 2020. Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19
32361099 2020. The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19
32344315 2020. N-acetyl-cysteine may prevent COVID-19-associated cytokine storm and acute respiratory distress syndrome
32353741 2020. Phytotherapeutics and SARS-CoV-2 infection: Potential role of bioflavonoids
32344313 ä. Can pioglitazone be potentially useful therapeutically in treating patients with covid-19?
32344312 2020. Potential effect of natural and anabolizan steroids in elderly patient with COVID-19
32344310 2020. Respiratory conditions in coronavirus disease 2019 (COVID-19): Important considerations regarding novel treatment strategies to reduce mortality
32344308 2020. Suggesting Ritonavir against COVID-19/SARS-CoV-2
32339778 ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19
32339777 2020. May IL-17 have a role in COVID-19 infection?
32335456 2020. The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?

C7158785 ä. Convalescent plasma: A possible treatment of COVID-19 in India
32217166 2020. Chloroquine and COVID-19, where do we stand??
32240719 ä. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection
32353355 ä. Testosterone, a key hormone in the context of COVID-19 pandemic
32344177 2020. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect
32305500 ä. Chloroquine paradox may cause more damage than help fight COVID-19
32370766 2020. Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
32307014 2020. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19
32255312 2020. A possible probiotic (S salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2
32365556 2020. Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-gamma as Candidates for Cytokine Storm Modulation in COVID-19 Disease
32316270 2020. COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help
32231349 2020. Chloroquine in COVID-19: the evidence
32231348 2020. Emerging prophylaxis strategies against COVID-19
32291351 2020. Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data
32187464 ä. A Trial of Lopinavir?Ritonavir in Adults Hospitalized with Severe Covid-19
32187463 ä. Covid-19 ? The Search for Effective Therapy
32275812 ä. Compassionate Use of Remdesivir for Patients with Severe Covid-19
32354113 2020. On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges
32326343 2020. Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2?
32366817 2020. A human monoclonal antibody blocking SARS-CoV-2 infection
32203437 ä. Insights from nanomedicine into chloroquine efficacy against COVID-19
32358580 ä. COVID-19: a case for inhibiting IL-17?
32358579 ä. Will helminth co-infection modulate COVID-19 severity in endemic regions?
32296135 ä. COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
32355330 ä. Inactivated vaccine for SARS-CoV-2
32327719 ä. Complement as a target in COVID-19?
32346092 ä. Cancer therapy tool informs COVID-19 vaccines
32346094 ä. COVID-19 vaccine design: the Janus face of immune enhancement
32317716 ä. The potential danger of suboptimal antibody responses in COVID-19

• A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing

32286538 ä. Human antibodies can neutralize SARS-CoV-2
32332922 ä. SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2
32327746 ä. Translating IL-6 biology into effective treatments
32341531 ä. Could BCG be used to protect against COVID-19?
32291449 ä. ADAM17 inhibition may exert a protective effect on COVID-19
32350818 ä. Chloroquine-induced QTc prolongation in COVID-19 patients

32322402 2020. Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19
32355564 2020. Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome
32322397 2020. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance
32313660 2020. A short review on antibody therapy for COVID-19
32372835 2020. Trials of BCG vaccine will test for covid-19 protection
32287799 2020. Drug trials under way
32353120 ä. Does Cigarette Smoking Protect Against SARS-CoV-2 Infection?
32242236 ä. COVID-19 and Smoking
32194995 2020. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
32340216 2020. Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections
32252338 2020. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths
32342019 ä. Exercise against SARS-CoV-2 (COVID-19): Does workout intensity matter? (A mini review of some indirect evidence related to obesity)
32258351 2020. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
32258207 2020. High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019
32363212 ä. Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
32292817 2020. Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19
32284951 2020. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
32214286 2020. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use
32098302 2020. Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development
32357471 2020. Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs
32333199 ä. Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19
32307559 ä. Management for patients with pediatric surgical disease during the COVID-19 epidemic
32215760 2020. Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond
32245264 2020. Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses
32290348 2020. COVID-19: A Brief Overview of the Discovery Clinical Trial
32371086 ä. The pros and cons of traditional Chinese medicines in the treatment of COVID-19
32145402 2020. Traditional Chinese medicine for COVID-19 treatment
32205232 2020. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)
32360585 ä. Current targeted therapeutics against COVID-19: based on first-line experience in china
32360584 ä. Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2
32360583 ä. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis
32360581 ä. Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for COVID-19 early management
32360580 ä. Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-kappaB signaling pathway
32251726 2020. The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good
32251725 ä. Reply to ?The use of traditional Chinese medicines to treat SARS-CoV-2 may cause more harm than good?
32360484 2020. Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study
32360480 ä. Candidate drugs against SARS-CoV-2 and COVID-19
32334052 2020. Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection
32325127 2020. Darunavir does not prevent SARS-CoV-2 infection in HIV patients
32247821 2020. 3CLpro inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials
32302707 ä. Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?: This paper is dedicated to Sofia Maione born during COVID-19 outbreak
32283223 2020. Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)
32322486 2020. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome
32369479 2020. Antibody-based therapies for COVID-19: Can Europe move faster?
32343686 2020. Pandemic responses: Planning to neutralize SARS-CoV-2 and prepare for future outbreaks

32054787 2020. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
32253318 2020. Effectiveness of convalescent plasma therapy in severe COVID-19 patients
32229574 2020. News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine
32275753 ä. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19
32342871 ä. Is low dose radiation therapy a potential treatment for COVID-19 pneumonia?
32342874 ä. Low dose radiation therapy for COVID-19 pneumonia: a double-edged sword
32327397 ä. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine

32354685 ä. Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia

32239125 2020. Remdesivir, la esperanza antiviral frente al SARS-CoV-2
32256547 2020. Clinical trials on drug repositioning for COVID-19 treatment
32267301 ä. Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes
32232552 ä. Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs
32124179 ä. Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need
32376987 2020. Inhibition of Influenza A virus propagation by benzoselenoxanthenes stabilizing TMPRSS2 Gene G-quadruplex and hence down-regulating TMPRSS2 expression
32278175 ä. COVID-19: A promising cure for the global panic
32253226 ä. (β-D-N4-hydroxycytidine (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
32358203 ä. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
32198291 2020. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved ?-ketoamide inhibitors
32321856 ä. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
32347055 2020. Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors
32341331 2020. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia
32347054 2020. Strategies for vaccine development of COVID-19
32133159 2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia
32366290 2020. Mesenchymal stem cells as a potential therapy for COVID-19
C7110269 ä. COVID-19 Outbreak: an Update on Therapeutic Options
32307653 ä. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement
32281052 ä. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future
32320535 2020. Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease 2019
32362735 ä. Insights into the inhibitory potential of selective phytochemicals against Mpro of 2019-nCoV: a computer-aided study
32347963 2020. An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19
32343358 2020. Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives - current situation and perspectives
32328234 2020. Does the direct renin inhibitor have a role to play in attenuating severity of the outbreak coronavirus disease 2019 (COVID-19)?
32360140 ä. Bee venom and SARS-CoV-2
32345485 ä. Treatment for emerging viruses: Convalescent plasma and COVID-19
32359789 ä. COVID-19 Convalescent Plasma: Now Is the Time for Better Science
32359788 ä. Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic
32289548 2020. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
32247925 ä. Repurposing antimalarials and other drugs for COVID-19
32145386 ä. Remdesivir as a possible therapeutic option for the COVID-19
32334088 ä. SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies?
32325121 ä. Tocilizumab: A new opportunity in the possible therapeutic arsenal against COVID-19
32247927 ä. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
32249063 ä. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
32362491 ä. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355?359; 2020)
32294562 ä. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease
32371057 ä. Potential applications of plant biotechnology against SARS-CoV-2
32291112 ä. Ongoing Clinical Trials for the Management of the COVID-19 Pandemic
32299202 2020. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
32293834 2020. Antiviral treatment of COVID-19
32295153 2020. What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?
32235387 2020. Progress and Prospects on Vaccine Development against SARS-CoV-2
32034638 ä. Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury
32297156 ä. Computational Identification of Small Interfering RNA Targets in SARS-CoV-2
32360300 ä. Natural product-derived phytochemicals as potential agents against coronaviruses: a review
32363219 ä. Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock
32106567 2020. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies
32098094 2020. Structural Basis for Inhibiting Porcine Epidemic Diarrhea Virus Replication with the 3C-Like Protease Inhibitor GC376
32272550 2020. Antiviral Agents: Discovery to Resistance
32268515 2020. In Silico Discovery of Candidate Drugs against Covid-19
32357553 2020. Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19
32340120 2020. Shedding Light on the Effect of Natural Anti-Herpesvirus Alkaloids on SARS-CoV-2: A Treatment Option for COVID-19
32295237 2020. Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs
32313883 2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review)
C7118592 ä. Understanding of guidance for acupuncture and moxibustion interventions on COVID-19 (Second edition) issued by CAAM

32377965 ä. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality
32297520 2020. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
32297519 2020. COVID-19 and vitamin D?Is there a link and an opportunity for intervention?
32191676 2020. Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?
32286694 2020. Letter: Covid-19, and vitamin D Authors reply
32281109 2020. Letter: Covid-19, and vitamin D
32339299 2020. Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic?
32330314 2020. Is BCG vaccination affecting the spread and severity of COVID-19?
32349517 2020. Becoming a Faithful Defender: Traditional Chinese Medicine against Coronavirus Disease 2019 (COVID-19)
32164424 2020. COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease
32358817 2020. Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome
32282956 2020. Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab
32247518 2020. COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern?
32207983 2020. Covid-19 infection and mortality: a physiologist?s perspective enlightening clinical features and plausible interventional strategies
32314704 2020. Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency
32359210 2020. Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report
32324331 2020. COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine
32274985 2020. Novel Coronavirus Disease (COVID-19): The Need for Immunoprevention at Industrial Scale
32352178 2020. Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North-supports vitamin D as a factor determining severity Authors reply
32311755 2020. Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity

32329159 2020. Thoughts on What Chemists Can Contribute to Fighting SARS-CoV-2 - A Short Note on Hand Sanitizers, Drug Candidates and Outreach
32376597 2020. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series
32345616 2020. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19
32304395 2020. COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO Support

32380318 ä. Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection
32380316 ä. Convalescent plasma in Covid-19: Possible mechanisms of action
32380315 ä. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis
32376396 ä. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
32376395 ä. SARS-CoV-2 infection among patients with systemic autoimmune diseases

32376403 ä. Imatinib might constitute a treatment option for lung involvement in COVID-19

32376398 ä. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
32361195 ä. SARS-CoV-2 infection complicated by inflammatory syndrome Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?
32304139 ä. Progress and Concept for COVID?19 Vaccine Development
32213152 2020. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
32299796 2020. Antirheumatic agents in covid-19: is IL-6 the right target?

32366720 2020. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
32312781 2020. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
32205349 2020. Updated Approaches against SARS-CoV-2
32229155 2020. Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?
32339387 2020. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin
32282033 2020. Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic
32362106 2020. Management of conjunctivitis during the COVID-19 pandemic 2020
32302379 2020. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients
32366511 2020. Developing a vaccine for covid-19
32357949 2020. Covid-19: Remdesivir is helpful but not a wonder drug, say researchers
32217607 2020. Covid-19: what treatments are being investigated?
32217555 2020. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients
32209549 2020. Covid-19: trials of four potential treatments to generate "robust data" of what works
32340998 2020. Covid-19: What do we know so far about a vaccine?
32321732 2020. Remdesivir in covid-19
32359080 2020. Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?
32304110 2020. Dosing will be a key success factor in repurposing antivirals for COVID-19

32369612 2020. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma
32368792 2020. Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2

32329520 2020. Current pharmacological treatments for COVID-19: What s next?
32371479 2020. Cytokine Storm Drugs Move from CAR T to COVID-19
32303509 2020. Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19
32276929 2020. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?

32245590 2020. Traditional Chinese Medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP)

32379692 ä. Traditional Chinese Medicine treatment of COVID-19
32379639 2020. Herbal medicine for treatment of children diagnosed with COVID-19: A review of guidelines

32333649 2020. The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene
32378737 2020. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19
32356569 2020. Challenges in Drug Development Posed by the COVID-19 Pandemic: An Opportunity for Clinical Pharmacology
32246834 2020. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection
32350860 2020. Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2
32348551 2020. Response to: Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing: Quantitative Clinical Pharmacology Input to SARS-CoV-2 Therapeutics Should Be Based on Robust Data
32302411 2020. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19
32167153 2020. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
32345063 2020. Truncated IV acetylcysteine treatment duration has potential to safely preserve resources during the COVID-19 pandemic
32315229 2020. COVID-19 and the CRISPR Community Response
32321407 2020. Hispidin and Lepidine E: two Natural Compounds and Folic acid as Potential Inhibitors of 2019-novel coronavirus Main Protease (2019-nCoVMpro), molecular docking and SAR study

32334502 2020. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment
32133962 2020. Effective Chemicals against Novel Coronavirus (COVID-19) in China
32314492 ä. Doxycycline, a widely used antibiotic in dermatology with a possible anti?inflammatory action against IL?6 in COVID?19 outbreak
32237190 ä. What does androgenetic alopecia have to do with COVID?19? An insight into a potential new therapy
32227357 ä. COVID?19 treatment by repurposing drugs until the vaccine is in sight
32377559 ä. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus
32374010 2020. Are probiotics effective adjuvant therapeutic choice in patients with COVID-19?
32374009 2020. Potential mechanisms by which the oxygen-ozone (O2-O3) therapy could contribute to the treatment against the coronavirus COVID-19
32369103 ä. Sacubitril/valsartan in COVID-19 patients: the need for trials
32373994 2020. Could host cell receptor alteration prevent SARS-CoV-2 viral entry? - Hype or hope
32373992 2020. MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment
32373991 2020. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking
32362193 2020. Quadruple therapy for asymptomatic COVID-19 infection patients
32366131 2020. Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine
32336007 2020. DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19?
32224164 2020. COVID-19 and diabetes: Can DPP4 inhibition play a role?
32278585 2020. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab

32352361 2020. Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists
32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications
32281695 2020. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases
32379896 2020. Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs
31690127 2019. Identification of novel proteolytically inactive mutations in coronavirus 3C-like protease using a combined approach
32157732 ä. Harnessing the immune system via Fc?R function in immune therapy: a pathway to next?gen mAbs

32298218 2020. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19
32317431 2020. Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
32370727 2020. SARS-CoV-2 & Covid-19: Key-Roles of the Renin-Angiotensin System / Vitamin D Impacting Drug and Vaccine Developments

32338559 2020. Low dose radiation therapy for COVID-19 pneumonia: is there any supportive evidence?
32319538 2020. Zinc and respiratory tract infections: Perspectives for COVID19 (Review)
32310190 2020. Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19
32347747 2020. Can melatonin reduce the severity of COVID-19 pandemic?
32268052 2020. Vitamin D, Covid-19 and Children
32268051 2020. Optimisation of Vitamin D Status for Enhanced Immuno-protection Against Covid-19
32338164 2020. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective
32306860 2020. Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations
32306822 2020. Peptide-like and small-molecule inhibitors against Covid-19
32340551 2020. Natural products may interfere with SARS-CoV-2 attachment to the host cell
32329419 2020. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach
32329408 2020. Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease
32362235 2020. Understanding the binding affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures
32362243 2020. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target
32364041 2020. Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2
32364011 2020. FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication
32362217 2020. In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria
32362245 2020. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study
32345124 2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets
32340562 2020. A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2
32376368 ä. Identifying potential treatments of COVID-19 from Traditional Chinese Medicine (TCM) by using a data-driven approach
32228825 2020. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1
32171193 2020. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies
32367767 2020. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL(pro)): an in silico screening of alkaloids and terpenoids from African medicinal plants
32238094 2020. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach
32345140 2020. Stilbene-based natural compounds as promising drug candidates against COVID-19
32266867 2020. In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain)
32248766 2020. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19
32349031 2020. Role of Dipeptidyl Peptidase 4 Inhibitors in Diabetic Patients with Coronavirus-19 Infection
32173110 2020. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
32379348 2020. 3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2 using immunoinformatics

32227493 ä. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID?19
32219882 ä. Controversial treatments: An updated understanding of the coronavirus disease 2019
32104907 ä. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus?A possible reference for coronavirus disease?19 treatment option
32108352 ä. Clinical trial analysis of 2019?nCoV therapy registered in China
32379346 2020. ACE2 Activators for the Treatment of Covid 19 Patients
32374457 2020. The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections
32369191 2020. Tocilizumab for the treatment of severe coronavirus disease 2019
32356910 2020. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review
32232976 2020. CD-sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID-19)
32176361 2020. Potentially repurposing adamantanes for COVID-19
32270515 2020. Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?
32253759 2020. Tocilizumab treatment in COVID-19: A single center experience
32347974 2020. Metformin and COVID-19: A novel deal of an Old Drug
32239514 ä. Comments on Zhang et al: Clinical trial analysis of 2019?nCoV therapy registered in China
32236562 2020. Treating COVID-19 with Chloroquine

32320059 2020. Potential of live pathogen vaccines for defeating the COVID-19 pandemic: history and mechanism
32297988 2020. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis
32297985 2020. Evaluation of Antiviral Therapies for Coronavirus Disease 2019 (COVID-19) Pneumonia in Shanghai, China
32297987 2020. Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection
32293713 2020. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China
32285942 2020. Defining Protective Epitopes for COVID-19 Vaccination Models
32281679 2020. COVID-19: Herd Immunity and Convalescent Plasma Transfer Therapy
32302456 2020. Potential of heparin and nafamostat combination therapy for COVID-19

32376627 2020. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity
32359402 2020. Considering BCG vaccination to reduce the impact of COVID-19
32380023 ä. Immunomodulation in COVID-19
32367857 2020. Safety of an immunomodulator Mycobacterium w in COVID-19
32367847 2020. Nasopharyngeal wash in preventing and treating upper respiratory tract infections: Could it prevent COVID-19?
32371362 2020. Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients
32366816 2020. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
32376359 ä. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2
32219429 2020. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges
32352484 2020. Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19
32208486 2020. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics
32297900 2020. Finding Effective Treatments for COVID-19: Scientific Integrity and Public Confidence in a Time of Crisis
32282022 2020. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
32347894 2020. The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19-First, Do No Harm
32243778 2020. Ensuring global access to COVID-19 vaccines
32247324 2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings
32251638 2020. Baricitinib for COVID-19: a suitable treatment?
32251639 2020. Baricitinib for COVID-19: a suitable treatment? - Authors reply

32372435 2020. Drug repurposing in the era of COVID-19: a call for leadership and government investment
32266987 2020. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)
32324177 2020. Some drugs for COVID-19
32162456 ä. Rapid Identification of Potential Inhibitors of SARS?CoV?2 Main Protease by Deep Docking of 1 3?Billion Compounds
32379955 ä. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
32375002 ä. Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery

32369286 2020. A Trial of Lopinavir-Ritonavir in Covid-19 Reply
32227757 2020. Developing Covid-19 Vaccines at Pandemic Speed
32289216 2020. Drug Evaluation during the Covid-19 Pandemic
32332765 2020. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
32273604 2020. Lopinavir-ritonavir in severe COVID-19
32273591 2020. The COVID-19 vaccine development landscape
32269311 2020. Coordinating the COVID-19 pipeline
32127666 2020. Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
32376938 2020. China is promoting coronavirus treatments based on unproven traditional medicines
32272481 2020. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors
32350436 2020. Hopes rise for coronavirus drug remdesivir
32355243 2020. Scores of coronavirus vaccines are in competition - how will scientists choose the best?
32353859 2020. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
32300225 2020. On the front lines of the coronavirus-vaccine battle
32346146 2020. The race for coronavirus vaccines: a graphical guide

32377399 2020. COVID-19 vaccines: breaking record times to first-in-human trials
32297843 2020. Oligonucleotides and the COVID-19 Pandemic: A Perspective
32380200 ä. In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS-CoV-2
32275178 2020. Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease
32216577 2020. Artificial intelligence and machine learning to fight COVID-19
32380051 ä. The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence
32352615 2020. Povidone-iodine gargle as a prophylactic intervention to interrupt the transmission of SARS-CoV-2
32209313 2020. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws
32285489 2020. Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity
32267566 2020. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19
32267560 2020. Considerations for Statin Therapy in Patients with COVID-19
32259313 2020. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
32281114 2020. Delayed Initiation of Remdesivir in a COVID-19-Positive Patient
32296012 2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia
32295694 2020. COVID-19 vaccination clinical trials should consider multiple doses of BCG
32326830 2020. Photobiomodulation and Antiviral Photodynamic Therapy as a Possible Novel Approach in COVID-19 Management
32330404 2020. Can Transdermal Photobiomodulation Help Us at the Time of COVID-19?
32352594 2020. Phytotherapic compounds against coronaviruses: Possible streams for future research
32347602 2020. Should we try the antiinflammatory natural product, celastrol, for COVID-19?
32350134 2020. Effective treatment of severe COVID-19 patients with tocilizumab
32365207 ä. Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report
32314850 2020. Melatonin: Roles in influenza, Covid?19, and other viral infections
32374874 ä. COVID-19: an unexpected indication for anti-rheumatic therapies?
32376603 ä. Development of an inactivated vaccine candidate for SARS-CoV-2
32352871 2020. A Radiation Mitigator as a Potential Treatment for COVID-19
32273254 2020. Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic
32167254 2020. Epidemie de coronavirus et polemique sur la chloroquine
32270942 2020. Covid-19, dans les brouillards francais de l'hydroxychloroquine
32301315 2020. Covid-19, dans les brouillards de l'hydroxychloroquine (2)
32301312 2020. Vaccins anti-covid-19 : les recherches de johnson & johnson, sanofi et pasteur
32355008 2020. COVID-19 shot protects monkeys
32292113 2020. Stem Cell?Based Therapy for Coronavirus Disease 2019
32272857 2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks
32360327 ä. Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence
32302280 2020. Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department
32220178 2020. Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019
32374891 2020. Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design
32374890 2020. COVID-19 convalescent plasma: phase 2
32245869 2020. Possible treatment of Covid-19 with a therapeutic vaccine
32221001 2020. Possible method for the production of a Covid-19 vaccine
32324899 2020. Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy
32319102 2020. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma
32240545 2020. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?
32268018 2020. Analysis of medication characteristics of traditional Chinese medicine in treating coronavirus disease-19 based on data mining
32281335 2020. Research progress of intervention of Chinese herbal medicine and its active components on human coronavirus
32281333 2020. Analysis of property and efficacy of traditional Chinese medicine in staging revention and treatment of coronavirus disease 2019
32281332 2020. Study on medication regularity of traditional Chinese medicine in treatment of COVID-19 based on data mining
32281331 2020. Analysis on pattern of prescriptions and syndromes of traditional Chinese medicine for prevention and treatment of COVID-19
32281330 2020. Analysis on clinical study protocols of traditional Chinese medicine for coronavirus disease 2019

32281328 2020. Study on screening potential traditional Chinese medicines against 2019-nCoV based on Mpro and PLP
32281327 2020. Rapid establishment of traditional Chinese medicine prevention and treatment of 2019-nCoV based on clinical experience and molecular docking
32164085 2020. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia
32164084 2020. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia
32164080 2020. Potential antiviral therapeutics for 2019 Novel Coronavirus
32164081 2020. Pharmacotherapeutics for the new coronavirus pneumonia
32164077 2020. Pharmacotherapeutic about the new coronavirus pneumonia
32114746 2020. Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer
32234130 2020. Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)

C7203037 ä. (Vitamin-C; Ozone)Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19?
C7197234 2020. Safety concerns with higher dosage chloroquine in COVID-19 patients
C7197245 2020. Antimalarial use in COVID-19 patients requires close monitoring
C7180667 ä. Achilles heel of the killer virus: the highly important molecular targets for hitting SARS-CoV-2 that causes COVID-19
C7190525 2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients
C7152890 2020. Biomimetic nanoparticles as universal influenza vaccine
C7149307 ä. Die Anwendung der Traditionellen Chinesischen Medizin...
C7144855 ä. Protocolo de diagn�stico y tratamiento para COVID-19 mediante medicina tradicional china?
32292907 2020. Standing out from the crowd in treating COVID-19 the title has been idioted from Potential TRPV1 blockade to treat severe lung dysfunction in COVID-19 infection.
C7187737 ä. COVID-19 and the Rationale for Pharmacotherapy: A South African Perspective
C7167691 2020. (Deutsche Szene) Schutz vor und Hilfe bei Covid19 Infektionen
C7149252 2020. Traditionelle Chinesische Medizin ... Ein Bericht aus Wuhan...
32483554 ä. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19
32377965 ä. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality
C7189003 2020. Glukokortikoide und Covid-19
C7189010 2020. Biologika und Covid-19
C7162107 2020. Chloroquin gegen Corona?
C7187784 ä. Case Study: A Patient with Asthma, Covid-19 Pneumonia and Cytokine Release Syndrome Treated with Corticosteroids and Tocilizumab

32387535 ä. Asthma, biologics, corticosteroids, and coronavirus disease 2019

C7197606 ä. Antibody therapies for the treatment of COVID-19
32376396 2020. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
32380316 2020. Convalescent plasma in Covid-19: Possible mechanisms of action
32380318 2020. Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection
32380315 2020. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis
32376392 2020. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions
32387040 ä. Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?
32389697 ä. Plasmapheresis treatment in COVID-19?related autoimmune meningoencephalitis: Case series
32475597 2020. The important role of polysaccharides from a traditional Chinese medicine-Lung Cleansing and Detoxifying Decoction against the COVID-19 pandemic
32437659 2020. Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection

32376238 2020. (rev on nat.prod.pharmacophores)Plants derived therapeutic strategies targeting chronic respiratory diseases: Chemical and immunological perspective
32391065 2020. Traditional Chinese medicine contributes to the treatment of COVID-19 patients
32402416 ä. Perforacion intestinal en paciente COVID-19 en tratamiento con tocilizumab y corticoides ...
C7186126 ä. Proposed use of thalidomide for the cytokine storm of COVID-19
32379639 2020. Herbal medicine for treatment of children diagnosed with COVID-19: A review of guidelines
32379692 2020. Traditional Chinese Medicine treatment of COVID-19
C7151553 2020. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles? heel conserved region to minimize probability of escape mutations and drug resistance

32129977 2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases
29115746 2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies
29717819 2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens
28945945 2017. Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses
32205350 2020. Tilorone, a Broad-Spectrum Antiviral for Emerging Viruses
21093489 2011. (x)Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model
20727913 2010. (x)Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus
16621037 2006. (x)Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin
31073993 2019. (x)Synthesis and anti?coronavirus activity of a series of 1?thia?4?azaspiro 4 5 decan?3?one derivatives
32223926 2020. Remdesivir attenuates high fat diet (HFD)-induced NAFLD by regulating hepatocyte dyslipidemia and inflammation via the suppression of STING

• Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus btu @OnlyTheGhosts

32285908 2020. Chloroquine and bafilomycin A mimic lysosomal storage disorders and impair mTORC1 signalling

32243785 2020. Embracing the Landscape of Therapeutics

17806092 2008. Ferrocene Conjugates of Chloroquine and other Antimalarials: the Development of Ferroquine, a New Antimalarial
30993690 2019. Emerging viruses and current strategies for vaccine intervention
23607598 2013. (x)Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome
32099652 2020. Frontiers in antiviral therapy and immunotherapy

32259744 2020. DNA vaccines: prime time is now
32387642 2020. Innovations in structure-based antigen design and immune monitoring for next generation vaccines
C7163352 ä. Cell-Based Therapies for COVID-19: Proper Clinical Investigations are Essential

32382358 ä. COVID-19 and Diabetes Mellitus: May Old Anti-diabetic Agents Become the New Philosopher?s Stone?
32377559 ä. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus
32387262 ä. Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment
C7194243 ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion
32383008 ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic
32344202 2020. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development
32387014 ä. Repositionnement de la chlorpromazine ... psychiatric patients could be protected from severe forms of COVID-19 by their psychotropic treatments
C7118608 ä. A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System
32292529 2020. Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19
32381323 ä. Acute hemolysis by hydroxycloroquine was observed in G6PD-deficient patient with severe COVD-19 related lung injury
C7117595 ä. Drug repurposing strategies for COVID-19
32348877 ä. Chemical evolution for taming the ?pathogenic kinase? PAK1
16022774 2005. (+)SARS Vaccine Development
28861908 2017. (+)Issues in vaccinology: Present challenges and future directions
31931639 2020. Dapsone as treatment adjunct in ARDS
16433589 2006. (+)Antiviral applications of RNAi for coronavirus
32318055 2020. Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics Tools

32362826 2020. Editorial: New Advances in RNA Targeting
32201439 2020. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach
32298965 2020. Blocking drug-induced autophagy with chloroquine in HCT-116 colon cancer cells enhances DC maturation and T cell responses induced by tumor cell lysate
32081774 2020. Discovery and development of safe-in-man broad-spectrum antiviral agents
32380291 ä. Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019
32387130 ä. GTS-21, an alpha7nAChR agonist, suppressed the production of key inflammatory mediators by PBMCs that are elevated in COPD patients and associated with impaired lung function
C7184982 ä. Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given

32389721 ä. Tocilizumab in COVID-19: Beware the risk of intestinal perforation
32294495 ä. Chloroquine as a prophylactic agent against COVID-19?
32386655 2020. Influence of immune aging on vaccine responses
32376368 2020. Identifying potential treatments of COVID-19 from Traditional Chinese Medicine (TCM) by using a data-driven approach
32451138 ä. ...surveillance ophtalmologique ...hydroxychloroquine e...
32446813 ä. Diagnosis and treatment of novel coronavirus pneumonia based on the theory of traditional Chinese medicine